- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07603310
Influence of Lung Recruitment Potential on Positive End-Expiratory Pressure (PEEP) Titration Strategies in Acute Respiratory Distress Syndrome (ARDS) Patients. (RECRUIT-PEEP)
Influence of the Lung Recruitment Potential on the Response to Two Positive End-Expiratory Pressure (PEEP) Titration Strategies in Patients With Acute Respiratory Distress Syndrome (ARDS)
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a prospective, randomized, open-label, parallel-group pilot study conducted at the Adult Intensive Care Unit of Hospital Dr. Franco Ravera Zunino (HFRZ). Eligible adult patients under invasive mechanical ventilation with moderate-to-severe ARDS within 36 hours of fulfilling Berlin criteria will be evaluated.
Prior to randomization, the patient's recruitment potential will be measured bedside using the R/I ratio (where > 0.5 indicates high recruitment potential and <= 0.5 indicates low potential). Eligible participants will then be randomized 1:1 into two PEEP titration groups:
- PEEP titration targeted to achieve the best static compliance of the respiratory system.
- PEEP titration guided by transpulmonary pressure measured via an esophageal balloon to target a positive end-expiratory transpulmonary pressure.
Crucially, immediately before starting the specific PEEP titration protocol in either group, an identical, standardized lung recruitment maneuver will be performed. This maneuver is executed in pressure-controlled ventilation (PCV) with a control pressure of 15 cmH2O, I:E ratio of 1:1, FiO2 1.0, starting with PEEP 5 cmH2O and increasing by 5 cmH2O every 10 seconds up to PEEP 25 cmH2O, maintaining a maximum peak pressure limit of 40 cmH2O for exactly 1 minute.
Standard baseline ventilator parameters will follow protective ventilation targets: volume-controlled ventilation, tidal volume 6-8 mL/kg of predicted body weight, respiratory rate adjusted to keep pH 7.25-7.45, plateau pressure < 28 cmH2O, and driving pressure < 14 cmH2O. Physiological parameters (PaO2/FiO2, driving pressure, ventilatory ratio, static compliance) will be recorded at 1, 24, 48, and 72 hours. The primary outcome is the change in oxygenation (PaO2/FiO2 ratio) at 24 hours. The study will explore how the baseline phenotype of lung recruitability alters early mechanical and gas exchange outcomes.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Esteban Santis, RT.
- Telefonnummer: +56 940367716
- E-post: esteban.santis@ogb.cl
Studera Kontakt Backup
- Namn: Hospital Dr. Franco Ravera Zunino
- Telefonnummer: +56 729383
- E-post: carolina.lindsay.brain@gmail.com
Studieorter
-
-
Región del Libertador General Bernardo O’Higgins
-
Rancagua, Región del Libertador General Bernardo O’Higgins, Chile, 2820000
- Rekrytering
- Dr. Franco Ravera Zunino Hospital
-
Kontakt:
- Renatto Anfossi
- Telefonnummer: +569 722729383
- E-post: ranfossi.hrlbo@gmail.com
-
Kontakt:
- Carolina Lindsay, PhD
- Telefonnummer: +56 72 2 729383
- E-post: c.lindsay.hfrz@gmail.com
-
Huvudutredare:
- Esteban Santis
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Diagnosis of moderate or severe Acute Respiratory Distress Syndrome (ARDS) according to the Berlin definition: acute onset, bilateral opacities not fully explained by heart failure or fluid overload, and Partial pressure of oxygen in arterial blood/Fraction of inspired oxygen <= 200 mmHg with Positive End-Expiratory Pressure (PEEP) >= 5 cmH2O.
- ARDS duration < 36 hours since fully meeting Berlin consensus criteria.
- Relative hemodynamic stability: absence of refractory shock, defined as norepinephrine dose <= 0.5 mcg/kg/min.
Exclusion Criteria:
- Evidence of active pulmonary air leaks (bronchopleural fistula, pneumothorax, pneumomediastinum).
- Severe uncorrected hemodynamic instability (norepinephrine > 0.5 mcg/kg/min).
- Contraindications for esophageal balloon placement (esophageal obstruction, known perforation, recent esophageal surgery, severe esophagitis).
- Elevated intracranial pressure or conditions where hypercapnia-induced increases in intracranial pressure must be avoided (intracranial hemorrhage, cerebral contusion, cerebral edema, mass effect with midline shift on CT).
- Known pregnancy.
- Severe coagulopathy (platelet count < 5,000/uL or INR > 3).
- Airway opening pressure higher than 15 cmH2O (AOP > 15 cmH2O).
- History of severe neuromuscular disease or chronic respiratory disease.
- Having received invasive mechanical ventilation for more than 96 hours.
- Inability to obtain informed consent or refusal by the legal representative.
- Contained laparotomy (open abdomen).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Best Static Compliance Titration
Patients receive positive end-expiratory pressure (PEEP) titration guided by the best static compliance of the respiratory system after undergoing a standardized initial lung recruitment maneuver
|
Positive End-Expiratory Pressure (PEEP) Titration by Static Compliance: Following the initial recruitment maneuver, an individualized PEEP decremental titration step-protocol is performed to identify the specific PEEP level that maximizes the static compliance of the respiratory system, aiming to optimize the balance between alveolar recruitment and overdistension. Initial Lung Recruitment Maneuver : Prior to individualized PEEP titration, all participants in this arm will undergo an initial standardized lung recruitment maneuver. This procedure will be executed in Pressure-Controlled Ventilation (PCV) mode, utilizing a driving/control pressure of 15 cmH2O. The recruitment process will begin at a baseline Positive End-Expiratory Pressure (PEEP) of 5 cmH2O, followed by incremental steps of 5 cmH2O every 10 seconds until reaching a maximum PEEP of 25 cmH2O. A peak airway pressure limit of 40 cmH2O will be strictly maintained during the maneuver for a total duration of 1 minute.
Andra namn:
|
|
Experimentell: Transpulmonary Pressure Titration
Patients receive positive end-expiratory pressure (PEEP) titration guided by transpulmonary pressure estimation via an esophageal balloon catheter after undergoing an identical standardized initial lung recruitment maneuver.
|
Positive End-Expiratory Pressure (PEEP) Titration by Transpulmonary Pressure: Following the initial recruitment maneuver, PEEP is titrated and protocolized via real-time esophageal balloon monitoring to target and maintain a slightly positive expiratory transpulmonary pressure, minimizing cyclic alveolar collapse and overdistension. Initial Lung Recruitment Maneuver: Prior to individualized PEEP titration, all participants in this arm will undergo an initial standardized lung recruitment maneuver. This procedure will be executed in Pressure-Controlled Ventilation (PCV) mode, utilizing a driving/control pressure of 15 cmH2O. The recruitment process will begin at a baseline Positive End-Expiratory Pressure (PEEP) of 5 cmH2O, followed by incremental steps of 5 cmH2O every 10 seconds until reaching a maximum PEEP of 25 cmH2O. A peak airway pressure limit of 40 cmH2O will be strictly maintained during the maneuver for a total duration of 1 minute.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Early Oxygenation (PaO2/FiO2 Ratio).
Tidsram: Baseline and 24 hours post-PEEP titration
|
The change in gas exchange efficiency is calculated as the absolute difference between the baseline Partial pressure of oxygen in arterial blood (PaO2)/Fraction of inspired oxygen (FiO2) ratio and the PaO2/FiO2 ratio measured 24 hours after individualized Positive End-Expiratory Pressure (PEEP) titration.
|
Baseline and 24 hours post-PEEP titration
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Ventilatory Efficiency
Tidsram: Baseline, 24, 48, and 72 hours
|
Evaluated using the Ventilatory Ratio (VR), which correlates physiological dead space and minute ventilation.
|
Baseline, 24, 48, and 72 hours
|
|
Incidence of Elevated Airway Opening Pressure (AOP)
Tidsram: Pre-randomization (Baseline)
|
Proportion of patients exhibiting an airway opening pressure greater than 5 cmH2O.
|
Pre-randomization (Baseline)
|
|
Ventilator-Free Days (VFD)
Tidsram: Up to Day 28
|
Number of days alive and free from invasive mechanical ventilation within a 28-day window.
|
Up to Day 28
|
|
Evolution of Static Compliance of the Respiratory System
Tidsram: Baseline, 1, 24, 48, and 72 hours
|
Changes in static compliance calculated via the formula: Tidal Volume / (Plateau Pressure - Positive End-Expiratory Pressure).
|
Baseline, 1, 24, 48, and 72 hours
|
|
Evolution of Driving Pressure and Plateau Pressure
Tidsram: Baseline, 1, 24, 48, and 72 hours
|
Serial monitoring of driving pressure (Plateau Pressure - Positive End-Expiratory Pressure) and plateau pressure to evaluate lung stress.
|
Baseline, 1, 24, 48, and 72 hours
|
|
Incidence of Procedure-Related Adverse Events
Tidsram: Throughout mechanical ventilation (Up to 28 days)
|
Proportion of participants experiencing complications due to recruitment maneuvers or Positive End-Expiratory Pressure (PEEP) titration (e.g., severe hypotension, barotrauma).
|
Throughout mechanical ventilation (Up to 28 days)
|
Samarbetspartners och utredare
Utredare
- Studiestol: Francisco Cerda, RT., Hospital Dr. Franco Ravera Zunino
- Studiestol: Javier Astudillo, MD., Hospital Dr. Franco Ravera Zunino
- Studiestol: Jennifer Ayuso, RT., Hospital Dr. Franco Ravera Zunino
- Studiestol: Rodrigo Arevalo, RT., Hospital Dr. Franco Ravera Zunino
- Studiestol: Carlos Pellegrini, MD., Hospital Dr. Franco Ravera Zunino
- Huvudutredare: Esteban Santis, RT., Hospital Dr. Franco Ravera Zunino
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HFRZ-UPC-2026-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .